D-497-2013 Class III Terminated

Recalled by Teva Pharmaceuticals USA, Inc. — Sellersville, PA

FDA drug recall D-497-2013 was initiated by Teva Pharmaceuticals USA, Inc. on Mar 14, 2013 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing The recall status is terminated (terminated Jan 15, 2014). Affected quantity: 120,049 blister packs.

Recall details

Product Type
Drugs
Report Date
Jun 5, 2013
Initiation Date
Mar 14, 2013
Termination Date
Jan 15, 2014
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
120,049 blister packs

Product description

Camrese(TM) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg and Ethinyl Estradiol 0.01 Tablets, 2 Extended-Cycle Tablet Dispensers (NDC 0093-3134-82) and 1 Extended-Cycle Tablet Dispenser NDC 0093-3134-91), 91 Tablets Each, Rx only, TEVA Womens Health Inc., Subsidiary of TEVA Pharmaceuticals, Inc., Sellersville, PA

Reason for recall

Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing

Distribution pattern

Nationwide

Code information

NDC 0555-3134-82 and 0093-3134-91 -- lot numbers 33802566A, exp 3/2013; 33802967A, exp 8/2013; 33803529A, exp 10/2013; and 33803609A, exp 11/2013.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-497-2013
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-497-2013. Report a data issue: hello@regdatalab.com.